Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676033 · ClinicalTrials.gov registry record · Phase 1
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
A Phase 1 study of Richter Syndrome and Leukemia, Chronic Lymphocytic, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Active
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06676033 is a Phase 1 study of Richter Syndrome and Leukemia, Chronic Lymphocytic that is active but no longer recruiting, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 5 participants, below the 32-participant average among 12 other Richter Syndrome trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06676033, a Phase 1 study of Richter Syndrome and Leukemia, Chronic Lymphocytic, is active but no longer recruiting, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHLBI) investigators are experienced in testing samples treated with bsAb2,3 including epcoritamab in an ongoing pre-clinical collaboration with Genmab. Addressing the objectives of this correlative study will advance the science and clinical application of epcoritamab specifically as well as T-cell engaging bsAb in general as an emerging class of immunotherapy for cancer. The study is enrolling by invitation only.
Conditions Studied
Interventions
- DRUG epcoritamab
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06676033
The ClinicalTrials.gov registry entry for NCT06676033 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 32-participant average among 12 other Richter Syndrome trials with a reported enrollment target (84% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Richter Syndrome appearing as the primary indexed condition, and to 1 intervention - of which epcoritamab is the first listed.
NCT06676033 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06676033 about?
NCT06676033 is a clinical study titled "Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome". This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at mu...
What is the current status of trial NCT06676033?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-07-18. Estimated completion is 2027-07-01.
What conditions does trial NCT06676033 study?
This clinical trial studies the following conditions: Richter Syndrome, Leukemia, Chronic Lymphocytic.
What interventions are being tested in trial NCT06676033?
The interventions under investigation include: epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06676033?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06676033 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Richter Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
RECRUITING · Phase 1
-
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
ACTIVE NOT RECRUITING · Phase 1
-
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
COMPLETED · Phase 1
-
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.